An investigation published by The BMJ has questioned the transparency around the safety of GlaxoSmithKline's Pandemrix swine flu vaccine.
GSK is involved in an ongoing lawsuit that alleges the vaccine caused narcolepsy, which is what caused internal safety reports to surface. These reports suggest the possibility that serious safety issues had emerged for Pandemrix during the 2009 H1N1 vaccine campaigns, but that the company and health officials did not make the information public.
According to a BMJ analysis, Pandemrix had five times more adverse events reported than Arepanrix and another H1N1 vaccine manufactured by GSK.
GSK declined to answer theThe BMJ’s questions, citing ongoing litigation.
Read the full story
[javascriptSnippet]